Dominika Écsiová
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dominika Écsiová has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Martin Šimkovič
4th Department of Internal Medicine – Haematology, Faculty of Medicine in Hradec Králové University Hospital and Charles University in Prague Hradec Kralove Czech Republic
5 shared publications - Pavel Vodárek
4th Department of Internal Medicine – Hematology University Hospital Hradec Králové Hradec Králové Czech Republic
5 shared publications - Pavel Žák
4th Department of Internal Medicine – Hematology University Hospital Hradec Králové Hradec Králové Czech Republic
5 shared publications - Lukas Smolej
4th Department of Internal Medicine – Hematology University Hospital Hradec Králové Hradec Králové Czech Republic
4 shared publications - David Belada
4th Department of Internal Medicine - Hematology, University Hospital, Hradec Králové, Czech Republic
3 shared publications - Doris Vokurková
Institute of Clinical Immunology and Allergology University Hospital Hradec Kralove Hradec Kralove Czech Republic
2 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study
Background: Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion‐related reactions (IRRs) and prolonged administration increase patient burden and outpatient chair occupancy. Evidence on shortened obinutuzumab infusion in CLL remains limited. Aims: To evaluate the safety, feasibility, and clinical outcomes of a 2‐h obinutuzumab infusion protocol in treatment‐naïve CLL. Methods: This retrospective single‐center cohort study included 112 treatment‐naïve patients receiving venetoclax–obinutuzumab ( n = 72) or obinutuzumab–chlorambucil ( n = 40). From cycle 1 day 8 onward, patients were managed according to either a shortened‐infusion strategy (Short; n = 64) or a standard‐duration strategy (Long; n = 48). The primary outcome was IRR incidence and severity; secondary outcomes included chair time, response rate, and progression‐free survival. Results: IRR rates did not differ significantly between the Short and Long groups (71.9% vs. 83.3%; odds ratio, 0.51; 95% confidence interval, 0.17–1.41; p = 0.18). Most IRRs occurred during the first infusion (87.4%), before implementation of the shortened protocol. Because cycle 1 day 1 and day 2 were administered using the same standard protocol in both groups, the safety comparison relevant to the shortened‐infusion strategy begins at cycle 1 day 8; IRRs were infrequent from cycle 1 day 8 onward, and none occurred from cycle 1 day 15 onward, when eligible patients in the Short group were receiving the 2‐h infusion. Grade 2 reactions predominated (91.6%); no Grade 4 IRRs occurred among the 112 patients included in the analysis. The shortened protocol saved 1.8 h per visit and 11.2 h per patient (42%). No apparent adverse signal in response or progression‐free survival was observed. Conclusions: In frontline CLL care, a 2‐h obinutuzumab infusion from cycle 1 day 8 was feasible, safe, and substantially reduced chair time, supporting its use to improve outpatient treatment efficiency.
- 1 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessShortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study
Background: Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion‐related reactions (IRRs) and prolonged administration increase patient burden and outpatient chair occupancy. Evidence on shortened obinutuzumab infusion in CLL remains limited. Aims: To evaluate the safety, feasibility, and clinical outcomes of a 2‐h obinutuzumab infusion protocol in treatment‐naïve CLL. Methods: This retrospective single‐center cohort study included 112 treatment‐naïve patients receiving venetoclax–obinutuzumab ( n = 72) or obinutuzumab–chlorambucil ( n = 40). From cycle 1 day 8 onward, patients were managed according to either a shortened‐infusion strategy (Short; n = 64) or a standard‐duration strategy (Long; n = 48). The primary outcome was IRR incidence and severity; secondary outcomes included chair time, response rate, and progression‐free survival. Results: IRR rates did not differ significantly between the Short and Long groups (71.9% vs. 83.3%; odds ratio, 0.51; 95% confidence interval, 0.17–1.41; p = 0.18). Most IRRs occurred during the first infusion (87.4%), before implementation of the shortened protocol. Because cycle 1 day 1 and day 2 were administered using the same standard protocol in both groups, the safety comparison relevant to the shortened‐infusion strategy begins at cycle 1 day 8; IRRs were infrequent from cycle 1 day 8 onward, and none occurred from cycle 1 day 15 onward, when eligible patients in the Short group were receiving the 2‐h infusion. Grade 2 reactions predominated (91.6%); no Grade 4 IRRs occurred among the 112 patients included in the analysis. The shortened protocol saved 1.8 h per visit and 11.2 h per patient (42%). No apparent adverse signal in response or progression‐free survival was observed. Conclusions: In frontline CLL care, a 2‐h obinutuzumab infusion from cycle 1 day 8 was feasible, safe, and substantially reduced chair time, supporting its use to improve outpatient treatment efficiency.
- Open Access
- 9 August 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (15) , e7399
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy
Introduction: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied.Methods: We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first‐line treatment. Fifty‐five patients were evaluated again after the treatment with CIT.Results: We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1.Conclusions: CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.
- 9 August 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (15) , e7399
Open AccessComplex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy
Introduction: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied.Methods: We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first‐line treatment. Fifty‐five patients were evaluated again after the treatment with CIT.Results: We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1.Conclusions: CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.
- Open Access
- 28 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 6956-6970
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia
Background: In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively studiedMethods: We used multi‐color flow cytometry, to prospectively measure absolute and relative numbers of CD4+ and CD8+ T‐cells and their subsets in 45 patients with indolent untreated CLL, 86 patients indicated for first‐line treatment, and 34 healthy controls. In 55 patients, we analyzed the impact of CITResults: CLL patients had a significant increase in most cell populations in comparison to controls. Progression of CLL was characterized by significantly elevated counts with the exception of a lower percentage of naïve T‐cells. After treatment, the percentage of naïve T‐cells further decreased at the expense of effector memory T‐cells (TEM). In patients with indolent CLL, higher percentages of naïve CD4+ (p = 0.0026) and naïve CD8+ (p = 0.023) T‐cells were associated with a longer time to first treatment (TTFT). The elevation of CD4+ central memory T‐cells (TCM) (p = 0.27) and TEM (p = 0.003) counts and a higher percentage of CD4+ TEM (p = 0.0047), were linked with shorter TTFT. In treated patients, increased regulatory T‐cells count was associated with shorter time to next treatment (TTNT) (p = 0.042), while higher CD4+ TCM count with shorter TTNT (p = 0.035) and shorter overall survival (p = 0.041).Conclusion: Our results indicate that naïve cell depletion and CD4+ TCM and TEM increases are detrimental to CLL patients' prognosis.
- 28 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 6956-6970
Open AccessA comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia
Background: In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively studiedMethods: We used multi‐color flow cytometry, to prospectively measure absolute and relative numbers of CD4+ and CD8+ T‐cells and their subsets in 45 patients with indolent untreated CLL, 86 patients indicated for first‐line treatment, and 34 healthy controls. In 55 patients, we analyzed the impact of CITResults: CLL patients had a significant increase in most cell populations in comparison to controls. Progression of CLL was characterized by significantly elevated counts with the exception of a lower percentage of naïve T‐cells. After treatment, the percentage of naïve T‐cells further decreased at the expense of effector memory T‐cells (TEM). In patients with indolent CLL, higher percentages of naïve CD4+ (p = 0.0026) and naïve CD8+ (p = 0.023) T‐cells were associated with a longer time to first treatment (TTFT). The elevation of CD4+ central memory T‐cells (TCM) (p = 0.27) and TEM (p = 0.003) counts and a higher percentage of CD4+ TEM (p = 0.0047), were linked with shorter TTFT. In treated patients, increased regulatory T‐cells count was associated with shorter time to next treatment (TTNT) (p = 0.042), while higher CD4+ TCM count with shorter TTNT (p = 0.035) and shorter overall survival (p = 0.041).Conclusion: Our results indicate that naïve cell depletion and CD4+ TCM and TEM increases are detrimental to CLL patients' prognosis.
- 16 June 2021
- Published by Care Comm in Transfuze a hematologie dnes
- Vol. 27 (2) , 128-136
Changes in the immune system of untreated patients with chronic lymphocytic leukaemia – part 1: adaptive immunity
The biggest source of information for doctors – proLékaře.cz
- 16 June 2021
- Published by Care Comm in Transfuze a hematologie dnes
- Vol. 27 (2) , 128-136
Changes in the immune system of untreated patients with chronic lymphocytic leukaemia – part 1: adaptive immunity
The biggest source of information for doctors – proLékaře.cz
- 6 October 2020
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 51 (4) , e13421
Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia
High doses of corticosteroids in combination with rituximab remain an alternative in the treatment in relapsed or refractory chronic lymphocytic leukaemia (CLL) in the current era of targeted therapies. This study retrospectively evaluates the efficacy of an RCD (rituximab, cyclophosphamide and dexamethasone) regimen in the treatment of 51 patients with relapsed CLL (median age, 72 years). Unfavourable prognostic features, such as Rai stage III/IV, unmutated IGHV, del11q, TP53 mutation/deletion, complex karyotype and bulky lymphadenopathy, were frequent. The overall response or complete remission was of 57% and 7%, respectively, and the median progression‐free survival (PFS) was of 12.3 months, median time to next treatment 23.1 months and median overall survival 39.2 months. Significant independent predictors of shorter PFS were TP53 deletion/mutation, advanced Rai stage and ≥2 previous lines of treatment. The incidence of neutropenia grade ≥ 3 was of 13%. Serious (CTCAE grade 3‐5) infections were found in 20% of patients. Steroid‐induced diabetes or diabetes decompensation occurred in 20% patients. Treatment‐related adverse events resulted in RCD dose reduction in 35% of patients. In comparison with a historical R‐Dex patient group, the treatment response and/or toxicity in our group was largely similar. However, the substantial differences in the baseline clinical characteristics of the groups may affect this comparison. In conclusion, the RCD regimen is an active, time‐limited therapeutic strategy for elderly patients with relapsed CLL. Further, the results of our analysis indicate that the addition of cyclophosphamide to the R‐Dex regimen maintains a similar efficacy, even after 50% reduction in the dexamethasone dose.
- 6 October 2020
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 51 (4) , e13421
Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia
High doses of corticosteroids in combination with rituximab remain an alternative in the treatment in relapsed or refractory chronic lymphocytic leukaemia (CLL) in the current era of targeted therapies. This study retrospectively evaluates the efficacy of an RCD (rituximab, cyclophosphamide and dexamethasone) regimen in the treatment of 51 patients with relapsed CLL (median age, 72 years). Unfavourable prognostic features, such as Rai stage III/IV, unmutated IGHV, del11q, TP53 mutation/deletion, complex karyotype and bulky lymphadenopathy, were frequent. The overall response or complete remission was of 57% and 7%, respectively, and the median progression‐free survival (PFS) was of 12.3 months, median time to next treatment 23.1 months and median overall survival 39.2 months. Significant independent predictors of shorter PFS were TP53 deletion/mutation, advanced Rai stage and ≥2 previous lines of treatment. The incidence of neutropenia grade ≥ 3 was of 13%. Serious (CTCAE grade 3‐5) infections were found in 20% of patients. Steroid‐induced diabetes or diabetes decompensation occurred in 20% patients. Treatment‐related adverse events resulted in RCD dose reduction in 35% of patients. In comparison with a historical R‐Dex patient group, the treatment response and/or toxicity in our group was largely similar. However, the substantial differences in the baseline clinical characteristics of the groups may affect this comparison. In conclusion, the RCD regimen is an active, time‐limited therapeutic strategy for elderly patients with relapsed CLL. Further, the results of our analysis indicate that the addition of cyclophosphamide to the R‐Dex regimen maintains a similar efficacy, even after 50% reduction in the dexamethasone dose.